What it is
Progestogen is the umbrella term for hormones that act like the body's own progesterone. It includes micronized progesterone — chemically identical to what the ovaries make — and synthetic versions called progestins. In menopause care, its central job is protecting the uterine lining: when a woman with a uterus uses systemic estrogen, a progestogen is taken alongside it to keep the lining from building up. Women who have had a hysterectomy typically don't need one.
Common forms
Oral micronized progesterone capsules — commonly taken at bedtime — are the form most often discussed. Progestogens also come combined with estrogen in some patches and pills, and a hormonal IUD is sometimes discussed as another way to protect the uterine lining. Cyclic schedules (part of the month) versus continuous daily use is a common practical question for the visit.
When it comes up
Most often as the partner to systemic estrogen for women with a uterus. It also comes up on its own in perimenopause conversations — for cycle-related symptoms and sleep — since micronized progesterone taken at night is known for its mild sedative quality, which many women consider a feature rather than a side effect.
Common misconceptions
The biggest: that all progestogens are interchangeable. Micronized progesterone and the various synthetic progestins are related but not identical, and research suggests they may not behave identically — a nuance worth raising at a visit. A second misconception: that “bioidentical” progesterone requires a compounding pharmacy. FDA-approved micronized progesterone is already body-identical, with the manufacturing consistency that compounded products aren't required to demonstrate.
What women often notice
Not guaranteed, and not everyone — educational only. Many women notice drowsiness after taking micronized progesterone, which is exactly why it's commonly taken at bedtime, and some report their sleep feels deeper. A minority notice breast tenderness, bloating, or mood shifts — the kind of feedback worth bringing to a follow-up visit, since form and schedule can often be adjusted.
Questions you may wish to discuss
- Do I need a progestogen in my situation — and what happens if I use estrogen without one?
- What's the difference between micronized progesterone and synthetic progestins for me?
- Is a cyclic or continuous schedule more appropriate in my case?
- If it makes me drowsy, is bedtime timing the standard approach?
✓ EVIDENCE SNAPSHOT
Menopause guidelines are consistent on the core point: women with a uterus who use systemic estrogen need a progestogen (or an approved alternative) to protect the uterine lining, while women without a uterus generally use estrogen alone — and the choice among progestogen options is individualized.¹
Learn next
- Systemic estrogen therapy
- Sleep
- Bioidentical & compounded hormones
- Perimenopause cycle changes
- The North American Menopause Society (now The Menopause Society). The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767–794.
- Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA. 2017;318(10):927–938.
- The North American Menopause Society (now The Menopause Society). The 2020 Genitourinary Syndrome of Menopause Position Statement of The North American Menopause Society. Menopause. 2020;27(9):976–992.
- The North American Menopause Society (now The Menopause Society). The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society. Menopause. 2023;30(6):573–590.
- Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660–4666.
- Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
- American College of Obstetricians and Gynecologists. Practice Bulletin No. 141: Management of Menopausal Symptoms. Obstet Gynecol. 2014;123(1):202–216.